FDA Guides Makers on Faster Weight-Loss Device Approvals
Published Date: 3/13/2026
Notice
Summary
The FDA just released new guidance to help companies get their weight-loss medical devices approved faster and safer. This affects anyone making devices that claim to help with weight loss, with clear steps on testing and proving benefits before selling. The guidance is effective now, so expect smoother reviews and smarter investments in device development.
Analyzed Economic Effects
4 provisions identified: 4 benefits, 0 costs, 0 mixed.
Final Guidance for Weight-Loss Devices
On March 13, 2026, the FDA published a final guidance titled "Medical Devices with Indications Associated with Weight Loss--Premarket Considerations." The guidance gives recommendations on non-clinical testing and clinical study design to support premarket submissions for devices that claim weight loss or obesity treatment.
Specific Trial Design Clarifications Included
The final guidance explicitly discusses use of sham controls, statistical analysis using modified intent-to-treat populations, and inclusion of patient-reported outcomes as part of benefit-risk evaluation. It also references FDA's Q-Submission Program as a way to request feedback on proposed clinical study design.
Intended to Speed and Standardize Reviews
FDA states the recommendations reflect current review practices and are "intended to promote consistency and facilitate efficient review" of premarket submissions for weight-loss devices. The guidance consolidates two prior draft guidances into one final document to ease use.
No New Paperwork Collections Listed
The guidance states it contains no new collection of information under the Paperwork Reduction Act and refers to previously approved FDA collections with OMB control numbers such as 0910-0120, 0910-0231, 0910-0078, 0910-0844, 0910-0756, 0910-0485, 0910-0073, 0910-0130, and 0910-0119. Those existing approvals continue to apply.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-06478 — Determination of Regulatory Review Period for Purposes of Patent Extension; VYLOY
The FDA has officially set the review period for VYLOY, a human biological product, so its patent holder can apply for extra patent time. This affects the company behind VYLOY, giving them a chance to extend their patent protection and potentially boost profits. If anyone thinks the dates are wrong or wants to challenge the company’s review speed, they must act by June 2 or September 30, 2026.
2026-06481 — Determination of Regulatory Review Period for Purposes of Patent Extension; HYMPAVZI
The FDA has set the official review period for HYMPAVZI, a new human biological product, so its patent holder can apply for extra patent time. This affects the company behind HYMPAVZI and anyone interested in patent extensions. If you think the dates are wrong or want to challenge the company’s diligence, you have until June 2 or September 30, 2026, to speak up—potentially impacting patent length and market exclusivity.
2026-06480 — Determination of Regulatory Review Period for Purposes of Patent Extension; EMRELIS
The FDA has officially set the review period for EMRELIS, a medicine patent, so the patent owner can apply for extra protection time. If anyone thinks the dates are wrong, they have until June 2, 2026, to speak up. Also, people can challenge whether the patent owner was diligent during the review by September 30, 2026. This affects patent holders and could impact how long they keep exclusive rights to their product.
2026-06479 — Determination of Regulatory Review Period for Purposes of Patent Extension; ENFLONSIA
The FDA has set the official review period for ENFLONSIA, a human biological product, so its patent holder can apply for extra patent time. This affects the company behind ENFLONSIA and anyone interested in patent rules. If you think the dates are wrong or want to challenge the company’s review speed, you have until June 2 or September 30, 2026, to speak up—potentially impacting patent length and market exclusivity.
2026-06477 — Determination of Regulatory Review Period for Purposes of Patent Extension; ENCELTO
The FDA has officially set the review period for ENCELTO, a medicine patent, so the company can apply to extend its patent protection. This affects the drug maker by potentially giving them more time to exclusively sell ENCELTO, which can mean more money. If anyone thinks the dates are wrong or the company wasn’t diligent, they have until June 2 or September 30, 2026, to speak up.
2026-06483 — Determination of Regulatory Review Period for Purposes of Patent Extension; INJECTAFER
The FDA has officially set the review period for INJECTAFER, a drug patent up for extension. This means the company can apply to extend their patent protection, potentially keeping their exclusive rights longer and impacting competition and pricing. If anyone thinks the dates are wrong or the company wasn’t diligent, they can speak up by June 2 or September 30, 2026.
Previous / Next Documents
Previous: 2026-04917 — Agency Information Collection Activities: Request for Comments for a New Information Collection
The Federal Highway Administration wants your thoughts on a new way to collect info about training programs for highway construction workers. This helps make sure workers get the right skills for new tech and growing job demands. If you’re involved in construction or training, you can comment by May 12, 2026—no cost to you, just your ideas!
Next: 2026-04920 — Submission for OMB Review; Comment Request
The Department of Defense wants your feedback on a new form for businesses and individuals asking for military help with productions. They’re collecting info to make sure requests follow rules and support is available. You’ve got until April 13, 2026, to share your thoughts—no money changes, just a quick 45-minute form if you apply.
Take It Personal
Get Your Personalized Policy View
Start a Free Government Policy Watch to see how policy affects your household, then upgrade to PRIA Full Coverage for year-round monitoring.
Already have an account? Sign in